Puristics – Enaltus

Puristics designs, manufactures and distributes four fully formulated skincare products and two feminine protection products

Pharus advised Scerene Healthcare, Inc. on the sale of Puristics™, its natural skin and feminine protection business, to Enaltus™.

Scerene Healthcare, Inc., launched its Puristic skincare business in January 2011 within the competitive persoanl care space. Puristics™ designs, manufactures and distributes four fully formulated skincare products and two feminine protection products through nationwide retail chains, including Walgreens, Rite-Aid, CVS and K-mart. The company’s products utilize naturally occurring ingredients and compounds, which are combined in a unique way for effective and safe use.

Other Transactions

Medimetriks Pharmaceuticals Inc., an independent branded dermatology company, has divested exclusive US rights to MM36 (difamilast ointment) to Acrotech Biopharma LLC in a transaction consisting of upfront and pre and post-approval milestone payments of up to $200 million.

New Jersey Medimetriks Pharmaceuticals Inc. divested exclusive US rights to MM36 (difamilast ointment)

Learn More 

R2 Dermatology (“R2”) announced today that it has entered into an exclusive distribution agreement with China’s Huadong Medicine Company Limited (“Huadong”) for the Asia-Pacific Region. In exchange, Huadong will make an equity investment in R2 Dermatology to fund R2’s next phase of product and market development.

San Ramon, CA R2 Technologies is the world leader in CryoAesthetics™ medical devices. Our Glacial® platform for precision contact cooling of the skin has been shown to reduce inflammation and also brighten dark spots.

Learn More 

vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that vTv Therapeutics LLC has entered into an exclusive licensing agreement with Newsoara Biopharma Co., Ltd. for rights to develop and commercialize vTv Therapeutics’ PDE4 Inhibitor program in Asia

High Point, NC Tv Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer’s disease and diabetes as well as treatment of inflammatory disorders.

Learn More 